Scrutiny of the UK’s medical hashish trade has not often, if ever, been so acute because it was legalised in 2018.
In March, the most important meta-analysis of cannabinoids as a major remedy for psychological problems thus far was printed in The Lancet Psychiatry, thrusting medical hashish into the worldwide media’s highlight like by no means earlier than.
Questions surrounding medical hashish and psychological well being remedy, and the prescribing practices of the trade at giant, have barely left pages of the UK’s nationwide media retailers since.
Some consider this scrutiny is lengthy overdue for a sector which has, regardless of the most effective efforts of many clinics, flown largely below the radar of the vast majority of Britons. Others consider it’s simply the newest remnant of prohibitionist rhetoric from the British press.
Graham Woodward, a registered psychological well being nurse with a long time of expertise navigating NHS requirements, CQC inspections, and MHRA rules, sees it otherwise. Now Chief Medical Officer at Releaf, one of many UK’s largest non-public hashish clinics, he views the present second not as a menace, however as a possibility – an opportunity to show that medical hashish, prescribed responsibly with psychiatric experience at its core, can and does meet the identical proof and governance requirements as every other medicine.
“I encourage, actually beg, anybody to return and take a look at our information and our apply,” Woodward tells MEDCAN24. “We’re an open ebook.”
From psychiatric nursing to hashish management
Woodward’s path to medical hashish was constructed on a basis of twin experience, understanding each the inside workings of UK healthcare regulation and the wants of sufferers with complicated psychological well being circumstances.
As a registered psychological well being nurse, he spent years working in psychiatric care, together with within the specialist discipline of drug dependancy. He stays a Specialist Advisor to the Care High quality Fee (CQC), giving him an insider’s view of how healthcare high quality is assessed and enforced throughout each NHS and personal sectors.
His path into medical hashish was formed by the scientific rigour and psychiatric complexity that critics accuse the trade of overlooking, together with six years at Indivior, an organization specialising in opioid dependancy remedy.
When Woodward joined Releaf as Chief Working Officer in January 2024, he constructed a crew of 55 prescribers, none of whom had earlier hashish prescribing expertise.
“We don’t have any of the legacy prescribers, the connoisseurs as they might see themselves,” Woodward explains. “We’ve individuals who got here to us desirous to study hashish, and have caught with us as a result of our governance ranges are superior, actually, to the NHS.”
Amongst these 55 are 4 guide psychiatrists and three psychiatric nurses, guaranteeing that psychiatric experience is positioned on the foundations of the clinic’s operations.
Any affected person the place psychiatry is recognized as a priority, even the place the first presenting situation is ache or one other bodily grievance, is rerouted to a psychiatric specialist earlier than any prescription is issued.
“We’ve by no means deviated from good apply and requirements,” Woodward says. “Any modifications that come via the CQC or round prescribing apply don’t concern me.”
A number of NHS consultants have left full-time NHS roles to work with Releaf, he suggests, drawn by its scientific governance construction, a number of multidisciplinary crew conferences held each day, designated physique standing for medical revalidation (which means docs don’t want NHS employment to take care of registration), and direct integration with NHS Backbone for accessing affected person data.
The rigour extends to prescribing choices. As MEDCAN24 reported not too long ago, between 30% and 40% of sufferers who full triage and attain a session nonetheless don’t obtain a prescription.
“A very powerful factor is that nobody pushes,” he says. “When you take a look at all the opposite clinics that go to 30%, 33% THC, they haven’t grown as a result of the viewers going to these are people who find themselves probably out and in of the leisure illicit market. We don’t comply with that.”
Final result-led, data-driven
Releaf has invested in licenses for 15 validated end result measurement instruments, together with GAD-7 for anxiousness, EQ-5D for high quality of life, BPI for ache, and PHQ-9 for despair, at a value of roughly £25,000 yearly.
“We invested on this as a result of we wish the info,” Woodward says.
The shortage of scientific proof argument, repeatedly cited by healthcare professionals within the NHS and its governing our bodies as a barrier to integration, is one thing Woodward and his crew at Releaf are actively working to mitigate.
“Professor Murray has by no means executed a head-to-head,” Woodward says, referring to the distinguished psychiatrist whose warnings about hashish and psychosis have featured in current protection.
Relating to the ever present protection of the Lancet examine, he argues that this can be a flawed methodology for drawing definitive conclusions on hashish efficacy.
“Everyone knows in a meta-analysis you may ask no matter you need and it offers you that reply. It’s fully completely different to the real-world proof now we have proper now utilizing validated instruments.”
“Why doesn’t somebody need to come and ask for the info? We might fortunately share it with anybody who desires to see it.”
Constructing infrastructure for scale
Past scientific supply, Woodward has taken on an advocacy position to assist put together the bottom for the sector to scale significantly.
The clinic has performed training workshops with police forces, together with a current session at Glass Pharms’ facility for Warwickshire Police, and is now working with a spread of organisations the place affected person discrimination generally happens.
These embody the SIA (Safety Trade Authority, liable for door safety at venues), social housing suppliers, Border Pressure, and ACAS, the office dispute decision service.
“The 2 largest points developing via our assist line are office discrimination and drug testing,” Woodward explains. “You’ll be able to flip as much as work with no matter medicine are on the BNF, however in the event you flip up with prescribed hashish, probably you might be dismissed, suspended, or marginalised.”
“We spoke to the heads of all these organisations, and so they’ve all stated they’ve had no direct suggestions that there’s been any considerations. However we’re solely at first, in the event you assume there’s probably two to a few million sufferers, why not get forward of the sport?”
The response, he says, has been universally constructive. “Each single one has been very eager to supply movies, posters, and PDFs they will ship to their workers. It’s very constructive.”
READ MORE…
Welcoming regulation as a aggressive benefit
Discuss amongst trade operators of a looming MHRA crackdown has, for a lot of, been a sword of Damocles hanging over the sector for a while. For Woodward, it’s a welcome intervention.
“The MHRA is tightening up on funky names, I hope that basically helps clear up the trade,” he says.
He helps the regulator’s push in the direction of lively pharmaceutical substances (APIs) moderately than completed merchandise, restrictions on high-THC sublingual oils (100mg/ml or greater), and crackdowns on vapes containing 80-90% THC that threat ‘unintentional misuse’.
“If companions we’re working with can’t adhere to MHRA guidelines and rules, they shouldn’t be on our formulary within the first place,” Woodward says. Roughly 50% of Releaf’s formulary comes from Glass Pharms, the UK’s largest home cultivator, with the rest rigorously sourced internationally.
As such, Releaf restricts the THC ratio for all its merchandise and sufferers at 25%. For youthful sufferers, this THC ratio cap is even stricter, and sufferers below the age of 21 are restricted to 30g per 30 days, whereas these below 25 are restricted to 60g per 30 days.
The regulatory double customary
Whereas welcoming regulatory intervention, Woodward argues that hashish remains to be held to greater requirements than nearly every other medical remedy.
Releaf is the one hashish clinic taking part in DICE (Digital Built-in Care Excellence), a month-to-month discussion board that features the MHRA, CQC, Promoting Requirements Authority and Normal Pharmaceutical Council, alongside main pharmacy chains like Lloyds.
“For the time being it’s all centered on GLP-1s – Ozempic, Wegovy, all these weight reduction drugs,” Woodward explains. “I’m always saying to the group, why are you able to get a GLP-1 so simply when it may trigger pancreatic points, gallbladder points, and but in the event you attempt to get a hashish prescription, you must leap via hoops?”
This widespread scrutiny and potential regulatory reform will likely be largely knowledgeable by an incoming ACMD overview.
“I submitted almost 13,000 phrases to the ACMD,” he says, although he’s cautious concerning the end result given the give attention to psychiatric threat moderately than affected person profit.
His supply to critics stays open. Come and look at the info, the governance, and the affected person outcomes.
“We don’t have to be unscrupulous to usher in sufferers,” Woodward says. “We do very properly for affected person acquisition by doing issues correctly.”
Scrutiny of the UK’s medical hashish trade has not often, if ever, been so acute because it was legalised in 2018.
In March, the most important meta-analysis of cannabinoids as a major remedy for psychological problems thus far was printed in The Lancet Psychiatry, thrusting medical hashish into the worldwide media’s highlight like by no means earlier than.
Questions surrounding medical hashish and psychological well being remedy, and the prescribing practices of the trade at giant, have barely left pages of the UK’s nationwide media retailers since.
Some consider this scrutiny is lengthy overdue for a sector which has, regardless of the most effective efforts of many clinics, flown largely below the radar of the vast majority of Britons. Others consider it’s simply the newest remnant of prohibitionist rhetoric from the British press.
Graham Woodward, a registered psychological well being nurse with a long time of expertise navigating NHS requirements, CQC inspections, and MHRA rules, sees it otherwise. Now Chief Medical Officer at Releaf, one of many UK’s largest non-public hashish clinics, he views the present second not as a menace, however as a possibility – an opportunity to show that medical hashish, prescribed responsibly with psychiatric experience at its core, can and does meet the identical proof and governance requirements as every other medicine.
“I encourage, actually beg, anybody to return and take a look at our information and our apply,” Woodward tells MEDCAN24. “We’re an open ebook.”
From psychiatric nursing to hashish management
Woodward’s path to medical hashish was constructed on a basis of twin experience, understanding each the inside workings of UK healthcare regulation and the wants of sufferers with complicated psychological well being circumstances.
As a registered psychological well being nurse, he spent years working in psychiatric care, together with within the specialist discipline of drug dependancy. He stays a Specialist Advisor to the Care High quality Fee (CQC), giving him an insider’s view of how healthcare high quality is assessed and enforced throughout each NHS and personal sectors.
His path into medical hashish was formed by the scientific rigour and psychiatric complexity that critics accuse the trade of overlooking, together with six years at Indivior, an organization specialising in opioid dependancy remedy.
When Woodward joined Releaf as Chief Working Officer in January 2024, he constructed a crew of 55 prescribers, none of whom had earlier hashish prescribing expertise.
“We don’t have any of the legacy prescribers, the connoisseurs as they might see themselves,” Woodward explains. “We’ve individuals who got here to us desirous to study hashish, and have caught with us as a result of our governance ranges are superior, actually, to the NHS.”
Amongst these 55 are 4 guide psychiatrists and three psychiatric nurses, guaranteeing that psychiatric experience is positioned on the foundations of the clinic’s operations.
Any affected person the place psychiatry is recognized as a priority, even the place the first presenting situation is ache or one other bodily grievance, is rerouted to a psychiatric specialist earlier than any prescription is issued.
“We’ve by no means deviated from good apply and requirements,” Woodward says. “Any modifications that come via the CQC or round prescribing apply don’t concern me.”
A number of NHS consultants have left full-time NHS roles to work with Releaf, he suggests, drawn by its scientific governance construction, a number of multidisciplinary crew conferences held each day, designated physique standing for medical revalidation (which means docs don’t want NHS employment to take care of registration), and direct integration with NHS Backbone for accessing affected person data.
The rigour extends to prescribing choices. As MEDCAN24 reported not too long ago, between 30% and 40% of sufferers who full triage and attain a session nonetheless don’t obtain a prescription.
“A very powerful factor is that nobody pushes,” he says. “When you take a look at all the opposite clinics that go to 30%, 33% THC, they haven’t grown as a result of the viewers going to these are people who find themselves probably out and in of the leisure illicit market. We don’t comply with that.”
Final result-led, data-driven
Releaf has invested in licenses for 15 validated end result measurement instruments, together with GAD-7 for anxiousness, EQ-5D for high quality of life, BPI for ache, and PHQ-9 for despair, at a value of roughly £25,000 yearly.
“We invested on this as a result of we wish the info,” Woodward says.
The shortage of scientific proof argument, repeatedly cited by healthcare professionals within the NHS and its governing our bodies as a barrier to integration, is one thing Woodward and his crew at Releaf are actively working to mitigate.
“Professor Murray has by no means executed a head-to-head,” Woodward says, referring to the distinguished psychiatrist whose warnings about hashish and psychosis have featured in current protection.
Relating to the ever present protection of the Lancet examine, he argues that this can be a flawed methodology for drawing definitive conclusions on hashish efficacy.
“Everyone knows in a meta-analysis you may ask no matter you need and it offers you that reply. It’s fully completely different to the real-world proof now we have proper now utilizing validated instruments.”
“Why doesn’t somebody need to come and ask for the info? We might fortunately share it with anybody who desires to see it.”
Constructing infrastructure for scale
Past scientific supply, Woodward has taken on an advocacy position to assist put together the bottom for the sector to scale significantly.
The clinic has performed training workshops with police forces, together with a current session at Glass Pharms’ facility for Warwickshire Police, and is now working with a spread of organisations the place affected person discrimination generally happens.
These embody the SIA (Safety Trade Authority, liable for door safety at venues), social housing suppliers, Border Pressure, and ACAS, the office dispute decision service.
“The 2 largest points developing via our assist line are office discrimination and drug testing,” Woodward explains. “You’ll be able to flip as much as work with no matter medicine are on the BNF, however in the event you flip up with prescribed hashish, probably you might be dismissed, suspended, or marginalised.”
“We spoke to the heads of all these organisations, and so they’ve all stated they’ve had no direct suggestions that there’s been any considerations. However we’re solely at first, in the event you assume there’s probably two to a few million sufferers, why not get forward of the sport?”
The response, he says, has been universally constructive. “Each single one has been very eager to supply movies, posters, and PDFs they will ship to their workers. It’s very constructive.”
READ MORE…
Welcoming regulation as a aggressive benefit
Discuss amongst trade operators of a looming MHRA crackdown has, for a lot of, been a sword of Damocles hanging over the sector for a while. For Woodward, it’s a welcome intervention.
“The MHRA is tightening up on funky names, I hope that basically helps clear up the trade,” he says.
He helps the regulator’s push in the direction of lively pharmaceutical substances (APIs) moderately than completed merchandise, restrictions on high-THC sublingual oils (100mg/ml or greater), and crackdowns on vapes containing 80-90% THC that threat ‘unintentional misuse’.
“If companions we’re working with can’t adhere to MHRA guidelines and rules, they shouldn’t be on our formulary within the first place,” Woodward says. Roughly 50% of Releaf’s formulary comes from Glass Pharms, the UK’s largest home cultivator, with the rest rigorously sourced internationally.
As such, Releaf restricts the THC ratio for all its merchandise and sufferers at 25%. For youthful sufferers, this THC ratio cap is even stricter, and sufferers below the age of 21 are restricted to 30g per 30 days, whereas these below 25 are restricted to 60g per 30 days.
The regulatory double customary
Whereas welcoming regulatory intervention, Woodward argues that hashish remains to be held to greater requirements than nearly every other medical remedy.
Releaf is the one hashish clinic taking part in DICE (Digital Built-in Care Excellence), a month-to-month discussion board that features the MHRA, CQC, Promoting Requirements Authority and Normal Pharmaceutical Council, alongside main pharmacy chains like Lloyds.
“For the time being it’s all centered on GLP-1s – Ozempic, Wegovy, all these weight reduction drugs,” Woodward explains. “I’m always saying to the group, why are you able to get a GLP-1 so simply when it may trigger pancreatic points, gallbladder points, and but in the event you attempt to get a hashish prescription, you must leap via hoops?”
This widespread scrutiny and potential regulatory reform will likely be largely knowledgeable by an incoming ACMD overview.
“I submitted almost 13,000 phrases to the ACMD,” he says, although he’s cautious concerning the end result given the give attention to psychiatric threat moderately than affected person profit.
His supply to critics stays open. Come and look at the info, the governance, and the affected person outcomes.
“We don’t have to be unscrupulous to usher in sufferers,” Woodward says. “We do very properly for affected person acquisition by doing issues correctly.”
Hashish Regulation Assets in Poland
Discover important authorized pages about hashish cultivation, gross sales, and medical product rules in Poland. These sources will information you thru permissions, certifications, and compliance necessities.
-
Polish News Registration and Interests of Cannabis Businesses
-
Permissions for Cannabis Sales in Poland
-
Authorization for Importing or Manufacturing Medical Products
-
Permission for Manufacturing or Importing Medical Products
-
Certificate of Good Manufacturing Practices (GMP)
-
Registration of Medical Products in Poland